Day of Women and Girls in Science

3P Biopharmaceuticals joins International Day of Women and Girls in Science

11 February, 2020 | General

At 3P Biopharmaceuticals we celebrate the International Day of Women and Girls in Science, and we want to do so by appreciating and thanking each of the women that forms part of the 3P team. Science and innovation do not understand gender and at 3P Biopharmaceuticals it is a real fact. Out of the 270 […]

vaccine against equine strangles Strangvac

Validation batches of the vaccine against equine strangles Strangvac® is completed

28 January, 2020 | General

3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics has, together with the Swedish biotechnology company Intervacc AB and LIOF-Pharma (previously Praxis Pharmaceutical), completed the manufacturing process for the vaccine against equine strangles called Strangvac®. The validation production batches required for the forthcoming registration application to the European Medicines […]

First cellularized collagen membrane implant to regenerate heart tissue in patients with ischemic heart disease

2 January, 2020 | General

3P Biopharmaceuticals and Viscofan go ahead with this innovative project of regenerative medicine for cardiac use. 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, and Viscofan BioEngineering, the Business Unit within the Viscofan Group), go one step further in an innovative cell therapy product. […]

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

28 November, 2019 | General

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, the UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment. 3P Biopharmaceuticals and In3Bio began their partnership in early 2019 with 3P Biopharmaceuticals being selected to […]

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment

21 October, 2019 | General

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, and the American biotech company, Zhittya Genesis Medicine (Zhittya), have successfully accomplished a tech transfer. 3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer […]

3P Biopharmaceuticals receives FDA approval

18 September, 2019 | General

The FDA classified 3P facilities as acceptable for the manufacture of the target molecule, and appropriate for its commercialization in the US market, once the product is authorized. 3P Biopharmaceuticals a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection […]

The manufacturing process for Strangvac, the new vaccine against equine strangles, is proceeding according to plan

27 August, 2019 | General

The biotechnology company Intervacc has together with 3P Biopharmaceuticals, the contracted manufacturer of Strangvac, finalized the production of the drug substances on a commercial scale in compliance with GMP (Good Manufacturing Practice). “We are very pleased to announce that we have now manufactured the drug substances for several million doses of Strangvac, the new vaccine […]

3P Biopharmaceuticals welcomes Keensight Capital as majority shareholder

23 July, 2019 | General

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in the process development and GMP manufacturing of biologics announces Keensight Capital, one of the European leading players in Growth Buyout, specialist in the IT and Healthcare sectors, as its new major investor. The incorporation of this new main shareholder comes after INFARCO, […]

3P Biopharmaceuticals_Betalutin

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

26 June, 2019 | General

3P Biopharmaceuticals (3P) and Norwegian biopharmaceutical company Nordic Nanovector have extended their collaboration agreement for the biopharmaceutical development of Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment. The non-Hodgkin lymphoma (NHL) is cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. 3P and Nordic Nanovector started their […]

3P Biopharmaceuticals enters into manufacturing agreement with the Swedish company Affibody

6 June, 2019 | General

The arrangement covers process transfer, process development and GMP manufacture of Affibody’s candidate 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Swedish company Affibody for the process transfer, scale-up and GMP commercial manufacturing of a recombinant protein sole property of Affibody. […]